Literature DB >> 2785419

Detection of major histocompatibility complex class I-restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs.

R A Koup1, J L Sullivan, P H Levine, D Brettler, A Mahr, G Mazzara, S McKenzie, D Panicali.   

Abstract

Major histocompatibility (MHC)-restricted, human immunodeficiency virus type one (HIV-1)-specific, cytotoxic T lymphocytes (CTLs) were detected in the peripheral blood mononuclear cells (PBMCs) of HIV-1-infected individuals. Using a system of autologous B and T lymphoblastoid cell lines infected with recombinant vaccinia vectors (VVs) expressing HIV-1 gene products, we were able to detect HIV-1-specific cytolytic responses in the PBMCs of 88% of HIV-1-seropositive hemophiliac patients in the absence of in vitro stimulation. These cytolytic responses were directed against both HIV-1 envelope and gag gene products. The responses were resistant to natural killer (NK) cell depletion and were inhibited by monoclonal antibodies (MoAbs) to the T cell receptor, CD8 surface antigens, and MHC class I antigens, suggesting a classical MHC class I restricted, virus-specific CTL response.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785419

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection.

Authors:  G W Nelson; R Kaslow; D L Mann
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection.

Authors:  P Klenerman; R E Phillips; C R Rinaldo; L M Wahl; G Ogg; R M May; A J McMichael; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

3.  Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1.

Authors:  N V Sipsas; S A Kalams; A Trocha; S He; W A Blattner; B D Walker; R P Johnson
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

4.  Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-alpha), and TNF-beta when they encounter their target antigens.

Authors:  C Jassoy; T Harrer; T Rosenthal; B A Navia; J Worth; R P Johnson; B D Walker
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

5.  Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors.

Authors:  P A Moss; S L Rowland-Jones; P M Frodsham; S McAdam; P Giangrande; A J McMichael; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

6.  Phenotypic characterization of CD8+ T cell populations in HIV disease and in anti-HIV immunity.

Authors:  K C Watret; J A Whitelaw; K S Froebel; A G Bird
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

7.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector.

Authors:  John P Miller; Yongzhi Geng; Hwee L Ng; Otto O Yang; Paul Krogstad
Journal:  Vaccine       Date:  2009-05-03       Impact factor: 3.641

9.  Three epitopic peptides of the simian immunodeficiency virus Nef protein recognized by macaque cytolytic T lymphocytes.

Authors:  I Bourgault; A Venet; J P Levy
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

10.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.